Parliamentary Search

Written question asked by Christopher Chope (Conservative) on Wednesday, 1 June 2022, in the House of Commons. It was due for an answer on Wednesday, 8 June 2022 (named day). It was answered by Maggie Throup (Conservative) on Tuesday, 14 June 2022 on behalf of the Department of Health and Social Care.

Tixagevimab/cilgavimab

Question

To ask the Secretary of State for Health and Social Care, how many NHS patients in England have been treated with Evusheld to date; and when will that drug become generally available on prescription to those with immunosuppressed conditions to protect against covid-19.

Original answer

To date, Evusheld has not been made available to National Health Service patients. Evusheld was granted a conditional marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) on 17 March 2022. However, the initial positive trial data on Evusheld was published prior to the emergence of the Omicron variant.

The UK Health Security Agency is testing the efficacy of Evusheld against the Omicron variant and we are identifying appropriate patient cohorts and approaches to the potential deployment of pre-exposure prophylaxis. Determining the efficacy of Evusheld against the Omicron variant will be necessary prior to any procurement or deployment decisions.

It has since been corrected.

Secondary information

Type
Written question
Reference
11547
Session
2022-23
Related items
Tixagevimab/cilgavimab
Thursday, 13 October 2022
Written questions
House of Commons
Correction to Written Parliamentary Questions
Monday, 17 April 2023
Written statements
House of Commons
Notes
Information corrected on 17 April at 731 c10-2WS
Subjects
Prescriptions Immunosuppression Tixagevimab/cilgavimab
Contains statistics
Yes
Link
View this Written question on www.parliament.uk